Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

However, Pfizer has not been a good investment. Since 2000, Pfizer’s stock has jumped by about 120% while the iShares ...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on ...

Pfizer and Allergan have confirmed that they will merge in a $160 billion deal, with Ireland-domiciled Allergan acquiring the US pharma giant, and re-naming itself Pfizer. The deal is the biggest ...

Click here and access our complete analysis report ... investor Starboard, Pfizer has remained resilient. Its strategic alliances in the oncology space and continued investment in pipeline ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million in cash and a $350 million equity investment – with another $1.4 ...